Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
It is designed to be administered once weekly via a subcutaneous injection, and its primary purpose is the treatment of obesity and overweight
Legally, BPC-157 is not approved for human consumption by the FDA and cannot be marketed as a drug
injectable) Target issue (e.g., tendon repair vs
Side Effects & Safety Nausea up to 56% at higher FDA doses
Frequently Asked Questions Research References Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017) BPC 157 promotes tendon healing via tendon outgrowth, cell survival and cell migration, FAK and paxillin phosphorylation (Chang et al., J Appl Physiol, 2011) Regeneration or Risk
US$ 25.01
US$ 20.08
US$ 27.08
US$ 24.70
US$ 26.47
US$ 20.08
US$ 29.30
